Plus Therapeutics Rebrands as Cerenome; Core Risks Unchanged

What happened

Plus Therapeutics announced a mid-year business update including a corporate rebranding to Cerenome and a Nasdaq ticker change to CNSY, effective August 3, 2026. The company affirmed its 2026 guidance and reported positive CNSide commercial progress, but provided no new utilization metrics or financial details. The rebranding does not alter the fundamental challenges: Nasdaq bid-price compliance (deadline May 11, 2026), ongoing dilution risk from warrant overhang and equity facilities, and the need for CNSide orders to materialize from payer coverage. The stock continues to trade below $1, making a reverse split likely, and substantial doubt about going concern persists despite the January 2026 offering extending runway. Without tangible evidence of CNSide volume or a clinical de-risking event, the investment thesis remains unchanged.

Implication

Rebranding and ticker change are cosmetic. The stock remains a high-risk microcap dependent on near-term listing resolution and commercialization execution. Investors should monitor the May 11 bid-price deadline and Q3 2026 CNSide utilization disclosures. A position is only warranted if the company regains compliance without excessive dilution and demonstrates sustained test volume above management's >1,250 tests/year target.

Thesis delta

Thesis unchanged. The rebranding does not alter the core risks of dilution, Nasdaq compliance, and lack of CNSide revenue traction. The WAIT rating remains appropriate; there is no new evidence to increase conviction.